MedTrace Logo

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

NCT03356080 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-11-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate of the clinical efficacy and safety of DLAAG protocol in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome with blast excess

Conditions

Interventions

DRUG

Decitabine

Decitabine,iv,0.1-0.2mg/kg, Day1-Day3 per week,up to 3 weeks

DRUG

Cytarabine

cytarabine, iv,15mg/m2 q12h, Day1-Day10

DRUG

All-transretinoic acid

All-transretinoic acid, 45mg/d Day4-Day6;15mg/d Day7-Day20

DRUG

G-CSF

G-CSF 300ug,sc,Day 0 until CR is achieved

Sponsors & Collaborators

  • Shanghai Tong Ren Hospital

    lead OTHER

Principal Investigators

  • Ligen Liu · Shanghai Tong Ren Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-07
Primary Completion
2019-07-07
Completion
2020-07-07

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03356080 on ClinicalTrials.gov